Tamibarotene + Venetoclax + Azacitidine
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia
Trial Timeline
Aug 26, 2021 → Aug 12, 2024
NCT ID
NCT04905407About Tamibarotene + Venetoclax + Azacitidine
Tamibarotene + Venetoclax + Azacitidine is a phase 2 stage product being developed by Syros Pharmaceuticals for Acute Myeloid Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04905407. Target conditions include Acute Myeloid Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04905407 | Phase 2 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukemia